8666 related articles for article (PubMed ID: 1675189)
1. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody.
Takahashi H; Strutton GM; Parsons PG
Histopathology; 1991 Mar; 18(3):221-7. PubMed ID: 1675189
[TBL] [Abstract][Full Text] [Related]
2. Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index.
Tokuda Y; Mukai K; Matsuno Y; Furuya S; Shimosato Y; Takasaki Y; Saida T; Ishihara K
Arch Dermatol Res; 1992; 284(6):319-23. PubMed ID: 1363460
[TBL] [Abstract][Full Text] [Related]
3. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study.
Rieger E; Hofmann-Wellenhof R; Soyer HP; Kofler R; Cerroni L; Smolle J; Kerl H
J Cutan Pathol; 1993 Jun; 20(3):229-36. PubMed ID: 8103531
[TBL] [Abstract][Full Text] [Related]
4. Age-related proliferative activity in dermal melanocytic naevi detected by PCNA/cyclin expression.
Tu P; Miyauchi S; Miki Y
Br J Dermatol; 1993 Jul; 129(1):65-8. PubMed ID: 8103667
[TBL] [Abstract][Full Text] [Related]
5. Proliferative activity of primary cutaneous melanocytic tumours.
Kuwata T; Kitagawa M; Kasuga T
Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
[TBL] [Abstract][Full Text] [Related]
6. Proliferative activity in Spitz's naevi compared with other melanocytic skin lesions.
Hofmann-Wellenhof R; Rieger E; Smolle J; Kerl H
Melanoma Res; 1993 Oct; 3(5):313-7. PubMed ID: 7904841
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of proliferating cell nuclear antigen/cyclin in human skin.
Furukawa F; Imamura S; Fujita M; Kinoshita K; Yoshitake K; Brown WR; Norris DA
Arch Dermatol Res; 1992; 284(2):86-91. PubMed ID: 1351713
[TBL] [Abstract][Full Text] [Related]
8. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/Cyclin 19A2. Correlation with Ki-67 labeling.
Kamel OW; LeBrun DP; Davis RE; Berry GJ; Warnke RA
Am J Pathol; 1991 Jun; 138(6):1471-7. PubMed ID: 1675840
[TBL] [Abstract][Full Text] [Related]
9. Proliferative activities in Spitz nevus compared with melanocytic nevus and malignant melanoma using expression of PCNA/cyclin and mitotic rate.
Tu P; Miyauchi S; Miki Y
Am J Dermatopathol; 1993 Aug; 15(4):311-4. PubMed ID: 8105711
[TBL] [Abstract][Full Text] [Related]
10. Growth dynamics of acquired melanocytic nevi. Higher reactivity of proliferating cell nuclear antigen in junctional and compound nevi than intradermal nevi.
Tokuda Y; Saida T; Mukai K; Takasaki Y
J Am Acad Dermatol; 1994 Aug; 31(2 Pt 1):220-4. PubMed ID: 7913717
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of Spitz nevi and malignant melanoma with use of antibody to proliferating cell nuclear antigen.
Niemann TH; Argenyi ZB
Am J Dermatopathol; 1993 Oct; 15(5):441-5. PubMed ID: 7902020
[TBL] [Abstract][Full Text] [Related]
12. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
13. Proliferation antigens in cutaneous melanocytic tumors--an immunohistochemical study comparing the transferrin receptor and the Ki 67 antigen.
Soyer HP; Smolle J; Smolle-Juettner FM; Kerl H
Dermatologica; 1989; 179(1):3-9. PubMed ID: 2569990
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
[TBL] [Abstract][Full Text] [Related]
15. Antigens associated with tumor progression in melanocytic neoplasia.
Elder DE; Herlyn M
Pigment Cell Res; 1992; Suppl 2():136-43. PubMed ID: 1409415
[No Abstract] [Full Text] [Related]
16. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
[TBL] [Abstract][Full Text] [Related]
18. Proliferative activity of keratinocytes correlates with that of melanocytes in naevi and melanomas.
Tronnier M; Kämmerer R; Wolff HH
Arch Dermatol Res; 1995; 287(5):509-11. PubMed ID: 7625864
[No Abstract] [Full Text] [Related]
19. p53 expression is rare in cutaneous melanomas.
Saenz-Santamaría MC; McNutt NS; Bogdany JK; Shea CR
Am J Dermatopathol; 1995 Aug; 17(4):344-9. PubMed ID: 8600797
[TBL] [Abstract][Full Text] [Related]
20. Melanocytic activation in HIV-1 disease: HMB-45 staining in common acquired nevi. Military Medical Consortium for the Advancement of Retroviral Research.
Smith KJ; Skelton HG; Heimer W; Baxter D; Angritt P; Frisman D; Wagner KF
J Am Acad Dermatol; 1993 Oct; 29(4):539-44. PubMed ID: 7691905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
